ODTX

16.8807.96%
KL

Kim Lewis

Scientific Co-Founder

Dr. Kim Lewis, Ph.D., served as Scientific Advisory Board Member of BluMaiden BioScience Pte. Ltd until November 2024. Dr. Lewis has been a Member of Scientific Advisory Board at Flightpath Biosciences, Inc. and CureLab Oncology, Inc. He is a Scientific Co-Founder of Odyssey Therapeutics, Inc. Dr. Lewis is a leading expert in natural products discovery with several decades of experience. Along with his role at Odyssey, he is a University Distinguished Professor and Director of the Antimicrobial Discovery Center at Northeastern University. Prior to that, he was a Faculty Member at MIT, University of Maryland and Tufts University. Dr. Lewis has also authored over 100 papers, is a Fellow of the American Association for the Advancement of Science (AAAS), a Fellow of the American Academy of Microbiology, a Clarivate Analytics Highly Cited Researcher and a recipient of the NIH Director’s Transformative Award. Dr. Lewis received his Ph.D. from Moscow University.

Positions